New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.

(Reuters) -Dexcom (DXCM) shares tumbled 15% on Friday after executives signaled that the medical device maker's 2026 growth forecast could fall short of Wall Street expectations.mo Shares had fallen ...

Stifel projected that the 15-day sensor could enhance DexCom’s gross margin in 2026, potentially contributing to year-over-year EBITDA margin expansion. The firm acknowledged certain risks, including ...

Oct 31 (Reuters) - Dexcom (DXCM.O), opens new tab shares tumbled 12.8% on Friday after executives signaled that the medical device maker's 2026 growth forecast could fall short of Wall Street ...

DexCom receives a BUY rating due to strong growth, expanding margins, and the launch of Stelo, the first OTC CGM for non-insulin users. DXCM raised its 2025 outlook, targeting $4.6B+ in revenue, 62% ...

Investing.com - UBS maintained its Buy rating and $106.00 price target on DexCom (NASDAQ:DXCM) following a Friday sell-off triggered by concerns about the company’s G7 continuous glucose monitoring ...